Objective To investigate the clinical significance of human epididymis 4(HE4), carbohydrate antigen 125(CA125) and cytokeratin-19-fragment(CYFRA21-1) combined detection in the diagnosis of malignant ovarian tumor. Methods The sera of 85 patients with malignant ovarian tumor, 85 patients with benign ovarian tumor and 85 healthy women(healthy control group) were collected. The serum levels of HE4 were determined by enzyme-linked immunosorbent assay(ELISA). The serum levels of CA125 and CYFRA21-1 were determined by chemiluminescence assay. The results of the 3 biomarkers were analyzed comparatively in different groups, and the positive rates of the 3 individual detections and the combined detection were analyzed. Results Serum HE4, CA125 and CYFRA21-1 levels in malignant ovarian tumor group were significantly higher than those in benign ovarian tumor group and healthy control group(P<0.01). The positive rates of HE4, CA125, CYFRA21-1 and the combined detection of the 3 biomarkers were 88.24%, 74.12%, 77.65% and 98.82%, respectively. Conclusions The combined detection of HE4, CA125 and CYFRA21-1 shows the good auxiliary diagnosis significance for malignant ovarian tumor.